Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Neoplasms, Glandular and Epithelial 2Carcinoma 2Uterine Cervical Dysplasia 1Urogenital Neoplasms 1Ovarian Neoplasms 1Ovarian Diseases 1Neoplasms 1Neoplasm Metastasis 1Gonadal Disorders 1Genital Neoplasms, Female 1Genital Diseases, Female 1Female Urogenital Diseases and Pregnancy Complications 1Female Urogenital Diseases 1Endocrine System Diseases 1Endocrine Gland Neoplasms 1Adnexal Diseases 1

Interventions

pembrolizumab 23Paclitaxel 14Cyclophosphamide 13Carboplatin 12Specimen Handling 10Magnetic Resonance Spectroscopy 10Biopsy 9fludarabine 8Nivolumab 7Leucovorin 7Gemcitabine 7Fluorouracil 7Doxorubicin 7aldesleukin 6Oxaliplatin 6Cisplatin 6liposomal doxorubicin 5Topotecan 5Taxes 5Irinotecan 5Interleukin-2 5olaparib 4atezolizumab 4Hyperthermic Intraperitoneal Chemotherapy 4Drug Therapy 4seribantumab 3fludarabine phosphate 3durvalumab 3dostarlimab 3dehydroftorafur 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm Metastasis × Ocoxin × Gynecologic × Clear all
NCT03562897 2022-07-06

Evaluation of Ocoxin-Viusid® in Advanced or Metastatic Ovarian Epithelial Cancer

Catalysis SL

Phase 2 Completed
40 enrolled
Gynecologic

Adnexal Diseases, Carcinoma, Endocrine System Diseases, Endocrine Gland Neoplasms, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Female, Genital Neoplasms, Female, Gonadal Disorders, Neoplasm Metastasis, Neoplasms, Glandular and Epithelial, Ovarian Diseases, Ovarian Neoplasms, Urogenital Neoplasms, Female Urogenital Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡